Understanding molecular landscape of endometrial cancer through next generation sequencing

What we have learned so far?

Research output: Contribution to journalShort survey

4 Citations (Scopus)

Abstract

Endometrial cancer (EC) is among the most common gynecological cancers affecting women worldwide. Despite the early detection and rather high overall survival rate, around 20% of the cases recur with poor prognosis. The Next Generation Sequencing (NGS) technology, also known as massively parallel sequencing, symbolizes a high-throughput, fast, sensitive and accurate way to study the molecular landscape of a cancer and this has indeed revolutionized endometrial cancer research. Understanding the potential, advantages, and limitations of NGS will be crucial for the healthcare providers and scientists in providing the genome-driven care in this era of precision medicine and pharmacogenomics. This mini review aimed to compile and critically summarize the recent findings contributed by NGS technology pertaining to EC. Importantly, we also discussed the potential of this technology for fundamental discovery research, individualized therapy, screening of at-risk individual and early diagnosis.

Original languageEnglish
Article number409
JournalFrontiers in Pharmacology
Volume7
Issue numberNOV
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

Endometrial Neoplasms
Technology
High-Throughput Nucleotide Sequencing
Precision Medicine
Pharmacogenetics
Research
Health Personnel
Early Diagnosis
Neoplasms
Survival Rate
Genome
Therapeutics

Keywords

  • Early diagnosis
  • Endometrial cancer
  • Molecular landscape
  • Next generation sequencing
  • Precision medicine
  • Screening

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{c2d9649513b6482ebcbaebb08e1140f2,
title = "Understanding molecular landscape of endometrial cancer through next generation sequencing: What we have learned so far?",
abstract = "Endometrial cancer (EC) is among the most common gynecological cancers affecting women worldwide. Despite the early detection and rather high overall survival rate, around 20{\%} of the cases recur with poor prognosis. The Next Generation Sequencing (NGS) technology, also known as massively parallel sequencing, symbolizes a high-throughput, fast, sensitive and accurate way to study the molecular landscape of a cancer and this has indeed revolutionized endometrial cancer research. Understanding the potential, advantages, and limitations of NGS will be crucial for the healthcare providers and scientists in providing the genome-driven care in this era of precision medicine and pharmacogenomics. This mini review aimed to compile and critically summarize the recent findings contributed by NGS technology pertaining to EC. Importantly, we also discussed the potential of this technology for fundamental discovery research, individualized therapy, screening of at-risk individual and early diagnosis.",
keywords = "Early diagnosis, Endometrial cancer, Molecular landscape, Next generation sequencing, Precision medicine, Screening",
author = "Suhaimi, {Siti Syazani} and {Ab Mutalib}, {Nurul Syakima} and {A. Jamal}, {A. Rahman}",
year = "2016",
month = "11",
day = "1",
doi = "10.3389/fphar.2016.00409",
language = "English",
volume = "7",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Understanding molecular landscape of endometrial cancer through next generation sequencing

T2 - What we have learned so far?

AU - Suhaimi, Siti Syazani

AU - Ab Mutalib, Nurul Syakima

AU - A. Jamal, A. Rahman

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Endometrial cancer (EC) is among the most common gynecological cancers affecting women worldwide. Despite the early detection and rather high overall survival rate, around 20% of the cases recur with poor prognosis. The Next Generation Sequencing (NGS) technology, also known as massively parallel sequencing, symbolizes a high-throughput, fast, sensitive and accurate way to study the molecular landscape of a cancer and this has indeed revolutionized endometrial cancer research. Understanding the potential, advantages, and limitations of NGS will be crucial for the healthcare providers and scientists in providing the genome-driven care in this era of precision medicine and pharmacogenomics. This mini review aimed to compile and critically summarize the recent findings contributed by NGS technology pertaining to EC. Importantly, we also discussed the potential of this technology for fundamental discovery research, individualized therapy, screening of at-risk individual and early diagnosis.

AB - Endometrial cancer (EC) is among the most common gynecological cancers affecting women worldwide. Despite the early detection and rather high overall survival rate, around 20% of the cases recur with poor prognosis. The Next Generation Sequencing (NGS) technology, also known as massively parallel sequencing, symbolizes a high-throughput, fast, sensitive and accurate way to study the molecular landscape of a cancer and this has indeed revolutionized endometrial cancer research. Understanding the potential, advantages, and limitations of NGS will be crucial for the healthcare providers and scientists in providing the genome-driven care in this era of precision medicine and pharmacogenomics. This mini review aimed to compile and critically summarize the recent findings contributed by NGS technology pertaining to EC. Importantly, we also discussed the potential of this technology for fundamental discovery research, individualized therapy, screening of at-risk individual and early diagnosis.

KW - Early diagnosis

KW - Endometrial cancer

KW - Molecular landscape

KW - Next generation sequencing

KW - Precision medicine

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85003441506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003441506&partnerID=8YFLogxK

U2 - 10.3389/fphar.2016.00409

DO - 10.3389/fphar.2016.00409

M3 - Short survey

VL - 7

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - NOV

M1 - 409

ER -